NCT05604885View on ClinicalTrials.gov

A Dose-range Study of the Safety and Efficacy of Treatment in Adult Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate

PHASE2CompletedINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

November 30, 2022

Primary Completion Date

August 28, 2023

Study Completion Date

August 28, 2023

Conditions
Rheumatoid Arthritis
Interventions
DRUG

AP1189, 60 mg

AP1189 tablets for oral use

DRUG

AP1189, 80 mg

AP1189 tablets for oral use

DRUG

AP1189, 100 mg

AP1189 tablets for oral use

DRUG

Placebo

Matching placebo tablets for oral use

Trial Locations (1)

Unknown

Timofei Mosneaga Republican Clinical Hospital, Chisinau

All Listed Sponsors
collaborator

NBCD A/S

INDUSTRY

lead

SynAct Pharma Aps

INDUSTRY